Skip to main content
AML drug candidate secures $3.2 million in funding

The Leukemia & Lymphoma Society of Rye Brook will provide Poland-based Selvita S.A. with up to $3.25 million over four years to develop SEL120 as a treatment for acute myeloid leukemia. The Biotechnology Accelerator Division will help provide additional funding for further development of the SEL120 project.

Full Story: